ClinicalTrials.gg
CompletedNCT06107205Updated Apr 24, 2026

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

A Phase 1 interventional study of TTYP01 and Radicava in Healthy Adult Subjects, sponsored by Shanghai Auzone Biological Technology Co., Ltd.. Completed at 1 site in United States. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Shanghai Auzone Biological Technology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

This is a Phase 1, Randomized, Open-Label, Three-Treatment, Three-Period Crossover Study to Assess Bioequivalence and Safety of TTYP01 Tablets to Radicava® Injection, and Radicava ORS® in Healthy Adult Subjects Under Fasting Conditions.The objective is To characterize the bioequivalence、safety and tolerability of TTYP01 tablets and Radicava® injection or Radicava ORS®in healthy adult subjects under fasted conditions.In this study, 30 healthy adult subjects will receive TTYP01, or Radicava, orRadicava ORS in each period according to the randomization sequence.

Read the detailed description

This is a Phase 1, Randomized, Open-Label, Three-Treatment, Three-Period Crossover Study to Assess Bioequivalence and Safety of TTYP01 Tablets to Radicava® Injection, and Radicava ORS® in Healthy Adult Subjects Under Fasting Conditions.

The Primary objective is To characterize the bioequivalence of TTYP01 tablets (Test) and Radicava® injection (Reference 1) or Radicava ORS® (Reference 2) in healthy adult subjects under fasted conditions.

The secondary objective is To determine the safety and tolerability of TTYP01 tablets (Test), Radicava Injection (Reference 1), and Radicava ORS (Reference 2) in healthy adult subjects under fasted conditions.

In this open-label, randomized, 3-formulation, 3-period, crossover study, 30 healthy adult subjects will receive 1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T), or 1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes), or 1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2) after an overnight fast in each period according to the randomization sequence. Subjects will be randomized to 1 of 6 parallel sequences (5 subjects per sequence), with a washout period of at least 96 hours between the periods.

The approximate study period is 6 weeks, including screening and follow-up.

02

Conditions studied

  • Healthy Adult Subjects
03

In context

Lead sponsor

Shanghai Auzone Biological Technology Co., Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all inclusion criteria at screening (or as noted) to be eligible for study participation, as follows:

  1. signed and dated by the subject
  2. Healthy male and female subjects of any ethnic and racial origin, aged 20 to 45 years, inclusive
  3. Female subjects who:

    • Are (defined as a minimum of 12 consecutive months of spontaneous amenorrhea confirmed by a serum follicle-stimulating hormone level > 40 IU/L), or
    • Are surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation), confirmed by medical documentations, or
    • Are of must agree to use at least 1 highly effective method of from at least 1 month prior to the initiation of the study through 3 months after the final dose, where highly effective methods of contraception include:
    • Intrauterine device
    • Intrauterine system
    • Contraceptive implant
    • Combined injectable contraceptives
    • Hormonal oral contraceptives when used in combination with male condoms with spermicide
    • If a female subject confirms that her male partner(s) has been verified to be clinically sterile (ie, documented infertility or surgical sterilization), this method is acceptable as the only means of contraception

    Note: The following are not acceptable methods of contraception:

    • Periodic sexual abstinence (eg, calendar, ovulation, symptothermal, and post-ovulation methods), declaration of sexual abstinence for the duration of the study, withdrawal, and lactational amenorrhea method
    • Spermicides alone
    • Hormonal oral contraceptives alone
    • Male condoms used in combination with female condoms or
    • Agrees to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject.
  4. Male subjects who are sexually active and whose partners are females of child-bearing potential, even if surgically sterilized (ie, status post vasectomy), who:

    • Avoid sperm donation during the entire study period and through 90 days after the last dose of study drugs, and
    • Agree to practice effective barrier contraception, or
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject
  5. (BMI) of 19 to 30 kg/m2 (inclusive) (BMI = weight (kg)/(height [m])2)
  6. Non-smokers (defined as having abstained from tobacco- or nicotine-containing products [eg, cigarettes, chewing tobacco, snuff, nicotine patches, and electronic cigarettes] in the 6 months prior to screening), stable light smokers, and ex-smokers will be included. Stable light and ex-smokers are defined as follows: "A light smoker is defined as someone smoking ≤5 cigarettes per day; an ex-smoker is someone who has completely stopped smoking for at least 3 months."
  7. In good health, as determined by the investigator at screening and confirmed at check-in, with no findings from medical history, physical examination, 12-lead , vital signs measurements, and clinical laboratory evaluations
  8. Subjects must be willing to understand and able to comply with all research procedures and restrictions, and are able to communicate effectively with researchers.

Exclusion criteria

Exclusion Criteria:

Subjects will not be eligible for study participation if they meet any of the exclusion criteria at screening (or as noted), or will be discontinued at the discretion of the investigator in consultation with the medical monitor if they develop any of the exclusion criteria during the study.

  1. History of any or allergic reaction to active ingredients or of the study drugs (eg, known allergy to bisulfite containing foods such as bottled lemon juice, grape juice, canned fruits, wine, jam, jelly, etc.)
  2. Positive test result for infectious diseases at screening or baseline, including antibody, surface antigen, virus antibody, and syphilis antibody
  3. Positive alcohol test at screening or baseline, or has a history of alcohol abuse (alcohol consumption in excess of 1 standard drink per day for women and 2 standard drinks per day for men; whereby 1 standard drink is equivalent to 12 oz beer [5% alcohol], 5 ounces of wine [12% alcohol], and 1.5 ounces of 80 proof [40% alcohol])
  4. Females who are pregnant, planning to become pregnant, or breastfeeding during the study or within 3 months after the study; or have a positive pregnancy test result at screening or check-in
  5. Any abnormal physical examination, vital sign, , or laboratory values at screening or check-in that are considered by the investigator
  6. Special dietary requirements or restrictions and cannot follow a uniform diet
  7. History of febrile illness or evidence of active infection within 14 days prior to the first dose
  8. Any subject with SARS-CoV-2 infection, based on a rapid test or positive polymerase chain reaction for SARS-CoV-2, or subjects who received the SARS-CoV-2 vaccine within 1 month prior to the first dosing, or plans to have the vaccine within 1 month after the last dose
  9. Positive drug screen at screening or check-in, or has a history of drug abuse within the past 5 years
  10. Clinically significant interventional therapies (surgery, paracentesis, etc.) within 3 months prior to the study, or plan to have any surgeries during the study
  11. Blood loss of non-physiological reasons ≥ 400 mL (ie, trauma, blood collection, blood donation) within 3 months prior to the first dose of study drugs, or plan to donate blood during this study and within 1 month after the last dosing
  12. Currently uses more than 5 tobacco products (refer to inclusion criterion 6) per day
  13. Received an experimental agent (eg, vaccine, drug, biologic, device, blood product, or medication) within 3 months prior to the first dose of study drugs, or plans to receive another experimental agent during the duration of this study
  14. Is unwilling to abstain from alcohol-containing products and xanthine/caffeine-containing products, including any foods and beverages, within 48 hours prior to the first dose
  15. Used any over-the-counter medications or prescription drugs (other than hormone replacement therapy, oral , or 650 mg acetaminophen/day), nutritional supplements, or herbal medicines within 1 month from screening, unless, in the opinion of the investigator and sponsor, the drug will not interfere with study assessments
  16. Abnormal renal function estimated calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \< 90 mL/min/1.73 m2
  17. Abnormal of QTcF ≥ 450 msec for males or QTcF ≥ 470 msec for females (confirmed by repeated examination)
  18. History of hypokalemia or family history of long QT syndrome
  19. Any current or historical conditions that may interfere with the absorption/distribution/metabolism/excretion of the study drugs, in the opinion of the investigator (eg, dysphagia, gastrointestinal diseases)
  20. Any clinically relevant acute or chronic medical conditions or diseases of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune, or dermatologic systems that would pose a risk to subject's safety or interfere with the study assessments, as determined by the investigator
  21. Poor venous access (eg, history of difficult blood draws) for blood sample collection or intravenous dosing
  22. Any other conditions that would, in the opinion of the investigator, put the subjects at increased risk for participation in this study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Active comparator
    TTYP01

    Healthy subjects were administered 1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)

    Drug: TTYP01

  • Active comparator
    Radicava

    Healthy subjects were administered 1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)

    Drug: Radicava

  • Active comparator
    Radicava ORS

    Healthy subjects were administered 1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)

    Drug: Radicava ORS

Interventions

  • DrugTTYP01

    1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)

    Also known as: Edaravone tablets

  • 1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)

    Also known as: Edaravone injection

  • DrugRadicava ORS

    1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)

    Also known as: Edaravone ORS

06

What researchers measure

Primary outcomes

  1. PK Parameters-Area under the plasma concentration-time curve (AUC0-inf) from time 0 extrapolated to infinity of unchanged edaravone after TTYP01, Radicava and Radicava ORS administration

    Time frame: up to 48 hours each postdose

  2. PK Parameters- AUC from time 0 to the last measurable non-zero concentration(AUC0-t)of unchanged edaravone after TTYP01, Radicava and Radicava ORS administration

    Time frame: up to 48 hours each postdose

  3. PK Parameters - Maximum observed concentration (Cmax) of unchanged edaravone after TTYP01, Radicava and Radicava ORS administration

    Time frame: up to 48 hours each postdose

Secondary outcomes

  1. PK Parameters-Area under the plasma concentration-time curve (AUC0-inf) from time 0 extrapolated to infinity of sulfate and glucuronide metabolites after TTYP01, Radicava and Radicava ORS administration

    Time frame: up to 48 hours each postdose

  2. PK Parameters- AUC from time 0 to the last measurable non-zero concentration(AUC0-t)of sulfate and glucuronide metabolites after TTYP01, Radicava and Radicava ORS administration

    Time frame: up to 48 hours each postdose

  3. PK Parameters - Maximum observed concentration (Cmax) of sulfate and glucuronide metabolites after TTYP01, Radicava and Radicava ORS administration

    Time frame: up to 48 hours each postdose

  4. PK Parameters- Time to reach Cmax (Tmax)of unchanged edaravone, sulfate, and glucuronide metabolites after TTYP01, Radicava, and Radicava ORS administration

    Time frame: up to 48 hours each postdose

  5. PK Parameters - Apparent terminal elimination half-life (T1/2el)of unchanged edaravone, sulfate, and glucuronide metabolites after TTYP01, Radicava, and Radicava ORS administration

    Time frame: up to 48 hours each postdose

  6. PK Parameters - Apparent terminal elimination rate constant (Kel)of unchanged edaravone, sulfate and glucuronide metabolites after TTYP01, Radicava and Radicava ORS administration

    Time frame: up to 48 hours each postdose

  7. PK Parameters -Apparent oral drug clearance (parent drug only) (CL/F)of unchanged edaravone after TTYP01and Radicava ORS administration

    Time frame: up to 48 hours each postdose

  8. PK Parameters - Total clearance (CL) of unchanged edaravone after Radicava administration

    Time frame: up to 48 hours each postdose

  9. PK Parameters - Mean residence time (MRT)of unchanged edaravone after Radicava administration

    Time frame: up to 48 hours each postdose

  10. PK Parameters -Apparent volume of distribution Vz/F) of unchanged edaravone after TTYP01and Radicava ORS administration

    Time frame: up to 48 hours each postdose

  11. PK Parameters - Volume of distribution during terminal phase (Vz) of unchanged edaravone after Radicava administration

    Time frame: up to 48 hours each postdose

  12. Incidence and Number of Participants with Adverse events and adverse drug reactions

    Time frame: until the last follow-up visit, up to 6 weeks(including screening and follow-up)

07

Study locations

1 site
  • ICON Early Phase Services
    San Antonio, Texas 78209, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Oct 30, 2023
StartActual
Nov 7, 2023
Primary completionActual
Dec 14, 2023
CompletionActual
Dec 14, 2023
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06107205
Lead sponsor
Shanghai Auzone Biological Technology Co., Ltd.
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Nov 7, 2023
Primary completion
Dec 14, 2023
Completion
Dec 14, 2023
Last update
Apr 24, 2026

Study contacts

Robert. Bass, MD
principal investigator · ICON plc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion